Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study

0 402

Cited 9 times in

Authors: Min Seo Kim ; Se Yong Jung ; Seung Won Lee ; Han Li ; Ai Koyanagi ; Andreas Kronbichler ; Elena Dragioti ; Kalthoum Tizaoui ; Paul Wasuwanich ; Sung Hwi Hong ; Ramy Abou Ghayda ; Hae Won Yoo ; Hanna Kim ; Louis Jacob ; Joe-Elie Salem ; Karel Kostev ; Youn Ho Shin ; So Young Kim ; Gabriele Gamerith ; Dong Keon Yon ; Jae Il Shin ; Lee Smith

Citation: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, Vol.19(9) : 1970-1970.e3, 2021-09

MeSH: Adenosine Monophosphate / analogs & derivatives ; Adverse Drug Reaction Reporting Systems ; Alanine / analogs & derivatives ; COVID-19* / drug therapy ; Databases, Factual ; Drug-Related Side Effects and Adverse Reactions* / epidemiology ; Humans ; Pharmacovigilance ; SARS-CoV-2 ; World Health Organization

Abstract: Remdesivir has demonstrated clinical benefits in randomized placebo-controlled trials (RCTs) in patients with coronavirus disease 2019 (COVID-19)1-4 and was first approved for COVID-19 patients.5 However, whether remdesivir causes gastrointestinal adverse drug reaction (GI-ADRs) including hepatotoxicity is less clear.1-4,6 Therefore, we aimed to detect a diverse spectrum of GI-ADRs associated with remdesivir using VigiBase, the World Health Organization's international pharmacovigilance database of individual case safety reports.

Full Text: https://www.sciencedirect.com/science/article/pii/S1542356521004961

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers

Yonsei Authors: Shin, Jae Il(신재일) https://orcid.org/0000-0003-2326-1820
Jung, Se Yong(정세용) https://orcid.org/0000-0003-1337-563X

Show full item record Find it @ YMLIB

YUHSpace: Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study